Human papillomavirus (HPV) nucleic acid test kit (fluorescent PCR method) is a series of products developed for the rapid and accurate detection of HPV infection in response to different clinical needs. HPV4 kit can rapidly detect common high-risk types of HPV16, HPV18 and/or low-risk types of HPV6, HPV11, and can be used for rapid detection before vaccination, etc. HPV19 kit can comprehensively cover 19 high-risk types of HPV, which can rapidly detect high-risk types of HPV infection in a large number of samples to support timely clinical diagnosis and treatment decisions. HPV21 kit can accurately and rapidly type 19 high-risk types of HPV, which can rapidly support timely clinical diagnosis and treatment decisions. The HPV19 kit covers 19 high-risk HPV types, which can rapidly detect high-risk HPV infections in a large number of samples and support clinical diagnosis and treatment decisions in a timely manner.The HPV21 kit can accurately and rapidly type 19 high-risk HPV types and 2 low-risk HPV types, with extensive coverage and easy operation, providing comprehensive and accurate information for personalized clinical diagnosis and treatment. With high sensitivity, good specificity and highly stable performance, this series of products provides a rich and reliable choice for clinical detection of HPV infection.

Characteristics: Stable performance, applicable to a variety of difficult to handle samples (such as watery, lumpy, bloody, pus specimens, etc.), not subject to a variety of chemical and biochemical components (such as jell-o lotion residue ≤ 10%, hemoglobin ≤ 30mg / ml, etc.) interference; detection of specificity is good, and a variety of other types of HPV and similar pathogens without cross-reactivity; detection of high sensitivity, up to 50-1,000 copies / High sensitivity up to 50-1000 copies/reaction.

Applicable samples: Female cervical exfoliated cell samples

Cervical cancer is one of the common malignant tumors in women, and its prevalence is second only to breast cancer. There are about 130,000 new cases of cervical cancer and 30,000 deaths in China every year, which seriously threatens the health of our female population.

High-risk HPV testing and its combination with cervical cytology can significantly reduce the rate of missed diagnosis of cervical cancer and related lesions. More than 200 types of HPV have been identified, and persistent infection with high-risk HPV is the main cause of cervical cancer. Studies have shown that HPV infection can be detected in 99% of cervical cancer patients' cervical exfoliated cell samples, with HPV type 16 alone having a prevalence of more than 60% in this group. Low-risk HPV is highly associated with diseases such as flat warts and genital warts.

Several guideline consensus from WHO, FDA, ASCCP (American Society for Colposcopy and Cervical Pathology), IARC (International Agency for Research on Cancer) and other organizations recommend HPV testing for the female population aged 30-65. The 2017 edition of the Expert Consensus of the Expert Committee of the Colposcopy and Cervical Pathology Branch of the Chinese Eugenics Science Association clarifies the process of handling clinical cervical cytology, HPV testing and the combination of the two in China.

HPV testing can indicate the risk of recurrence after treatment in people with cervical cancer and related lesions. The chance of HPV infection in a person's lifetime is as high as 80%, and such people are at risk of re-infection or persistence of pre-infection after treatment, while high-risk HPV-infected people are at high risk of recurrence, so it is very important to monitor the dynamics of the HPV virus in the post-treatment population.

HPV testing can guide cervical cancer vaccination. In recent years, a variety of cervical cancer vaccines produced by different manufacturers have come on the market, and each vaccine does not target exactly the same HPV type. In order to achieve better immunization effect, you should test your own HPV infection status before vaccination, and choose reasonably for your own situation.